Senores Pharmaceuticals Ltd
Senores Pharmaceuticals Q3 FY25 earnings call: Revenue & Margins
Q3 FY25 earnings call: what management guided on revenue, margins and order book.
The short version
FY25 Q4 expected to be very strong, with full-year revenue projected between INR 410-440 crores. Strong growth expected: FY25 Q4 anticipated to be very strong with total revenue between INR 410-440 crores.
From Senores Pharmaceuticals Ltd's Q3 FY25 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- FY25 Q4 expected to be very strong, with full-year revenue projected between INR 410-440 crores.
- FY26 revenue anticipated to grow over 50%-60%, targeting INR 670-700 crores, driven mainly by CDMO/CMO and own product portfolio.
- CDMO/CMO revenue expected around $25-$30 million in FY26, with significant product launches ahead (15-17 in current quarter).
- Emerging markets showing strong potential with over 530 products under registration for pipeline growth.
- Own product portfolio to sustain strong growth with addition of new products annually (51 pipeline products could add $700-$800 million opportunity over 3 years).
2 more points from Senores Pharmaceuticals Ltd's call on revenue
Pro opens every point from 15K+ earnings calls
Profitability & Margins
See what Senores Pharmaceuticals Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Next year's planned CAPEX is firmly more than INR 200 crores, currently on the drawing board.
- A greenfield site in India is being scouted to cater to mid-tier emerging markets beyond the Ratnatris site.
- Injectable plant CAPEX: groundwork started, actual CAPEX begins Q1 next year, expected completion within 18-24 months; located at existing oral solid site with supporting infrastructure.
- Setting up backward integration for APIs primarily in India to improve cost competitiveness and supply security.
2 more points from Senores Pharmaceuticals Ltd's call on capex
Pro opens every point from 15K+ earnings calls
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Senores Pharmaceuticals Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- Senores has a strong and expanding order book driven by both CDMO/CMO contracts and own products in regulated markets.
- The CDMO/CMO vertical currently has 21 commercial products with a pipeline of 69 products expected to launch progressively.
- Around 15-17 CDMO/CMO products are targeted for commercialization in Q1 of FY26.
- They expect CDMO/CMO revenue for FY26 to be around $25 million to $30 million.
- The own product portfolio consists of 22+ products, with 5 more launches planned in Q4 FY25.
- The company has 51 own products in the pipeline, aiming to add more products annually.
2 more points from Senores Pharmaceuticals Ltd's call on order book
Pro opens every point from 15K+ earnings calls
Senores Pharmaceuticals Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹175 Cr, net profit ₹37 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Senores Pharmaceuticals Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Wockhardt Ltd (Q3 FY25)
725 crore, up 2% quarter-on-quarter and 2.2% year-on-year (Q3 FY24 revenue: Rs. Key concall takeaways from Wockhardt Ltd's Q3 FY25 earnings call — and how it…
- NGL Fine Chem Ltd (Q3 FY25)
Q3FY25 revenue from operations: ₹89.10 crores, a year-on-year (Y-o-Y) increase of 1.30% (Page 8). Key concall takeaways from NGL Fine Chem Ltd's Q3 FY25…
- Fermenta Biotech Ltd (Q3 FY25)
Q3-FY25 consolidated operational revenue: INR 1,565 Mn, up 58.1% YoY (Page 12) . Key concall takeaways from Fermenta Biotech Ltd's Q3 FY25 earnings call — and…
- Amrutanjan Health Care Ltd (Q3 FY25)
122.75 Cr, up 4.92% YoY (Q3 FY24: Rs. Key concall takeaways from Amrutanjan Health Care Ltd's Q3 FY25 earnings call — and how it ranks against sector peers.
Arthneeti Pro · Annual
Senores Pharmaceuticals Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Senores Pharmaceuticals Ltd Q3 FY25 results?
FY25 Q4 expected to be very strong, with full-year revenue projected between INR 410-440 crores. Strong growth expected: FY25 Q4 anticipated to be very strong with total revenue between INR 410-440 crores.
What is Senores Pharmaceuticals Ltd share price analysis?
Senores Pharmaceuticals Ltd currently shows a neutral. The stock trades at a P/E of 53.9 with a market cap of ₹6,805 Cr. Investors should review the full earnings analysis for detailed insights.
Is Senores Pharmaceuticals Ltd planning capital expenditure?
Next year's planned CAPEX is firmly more than INR 200 crores, currently on the drawing board.
Keep Senores Pharmaceuticals Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.